Angiotensin- (1-7) Peptide

Angiotensin- (1-7) Peptide

ProNeurogen Peptides are Selective Mas Receptor Agonists

ProNeurogen Peptides are Selective Mas Receptor Agonists

PNA5 Mechanism of Action

PNA5 Mechanism of Action

• PNA5 is a glycosylated-Angiotensin-(1-7) peptide related to the Renin-Angiotensin family

• PNA5 binds to small GPCR Mas receptor

• PNA5 activation of Mas results in inhibition of inflammation, ROS and increased brain blood flow via activation of e-NOS.

• Through these mechanisms, PNA5 actions result in neuroprotection and improved memory function.

PNA5 Mechanism of Action

• PNA5 is a glycosylated-Angiotensin-(1-7) peptide related to the Renin-Angiotensin family

• PNA5 binds to small GPCR Mas receptor

• PNA5 activation of Mas results in inhibition of inflammation, ROS and increased brain blood flow via activation of e-NOS.

• Through these mechanisms, PNA5 actions result in neuroprotection and improved memory function.

Chronic Neuropathic Pain

Approximately 100 million American adults suffer from chronic pain with an estimated societal cost of $600 billion annually.

Chronic pain continues to be an enormous unmet medical need with a far-reaching impact on society.

  • Novel approach – new  peptide drug class

  • Glycosylated-Ang-(1-7) Peptides

  • Target: MasR receptor

  • Mechanism: Anti-inflammatory

  • Excellent Brain Penetration

  • Efficacious for chronic bone pain, neuropathic pain

  • Extremely safe

ProNeurogen’s Pain Drug Candidates

ProNeurogen’s Pain Drug Candidates

ProNeurogen’s Pain Drug Candidates

Portfolio Expansion

Portfolio Expansion

PNA5 Mechanism of Action

Validated Mas receptor biology enables expansion into additional neurovascular, neurodegenerative, and neuroinflammatory disorders.

NEUROVASCULAR: Active human studies in traumatic brain injury and post-operative cognitive impairment with PNA1 demonstrate ready translation of PNA5 to human studies.

NEURODEGENERATIVE: Preclinical program in Parkinson's cognitive impairment and exploratory work in cerebral amyloid angiopathy extend the platform's reach into chronic disease.

NEUROINFLAMMATORY: NIH-funded development in neuropathic and inflammatory pain confirms mechanism continuity in peripheral and central inflammation.

Each expansion uses the shared biomarker suite and regulatory system, requiring no new infrastructure.

Validated Mas receptor biology enables expansion into additional neurovascular, neurodegenerative, and neuroinflammatory disorders.

NEUROVASCULAR: Active human studies in traumatic brain injury and post-operative cognitive impairment with PNA1 demonstrate ready translation of PNA5 to human studies.

NEURODEGENERATIVE: Preclinical program in Parkinson's cognitive impairment and exploratory work in cerebral amyloid angiopathy extend the platform's reach into chronic disease.

NEUROINFLAMMATORY: NIH-funded development in neuropathic and inflammatory pain confirms mechanism continuity in peripheral and central inflammation.

Each expansion uses the shared biomarker suite and regulatory system, requiring no new infrastructure.

Intellectual Property

Intellectual Property

PNA5 Mechanism of Action

Five patent families with 23 issued and four pending patents cover composition, formulation, and therapeutic use of Mas receptor analogs through 2042 under an exclusive University of Arizona license.


Five patent families with 23 issued and four pending patents cover composition, formulation, and therapeutic use of Mas receptor analogs through 2042 under an exclusive University of Arizona license.


Patent Portfoliio

Patent Portfolio

Patent Portfolio